Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

NCT03780283 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma
Lung Neoplasm
Small Cell Lung Cancer

Interventions

DRUG: Anlotinib Hydrochloride

Sponsor

First Hospital of Shijiazhuang City